Pear Bio - About the company
Pear Bio is a series A company based in London (United Kingdom), founded in 2017 by Duleek Ranatunga. It operates as a Developer of microfluidic chip for cancer drug research. Pear Bio has raised $14.2M in funding from Octopus Ventures. The company has 91 active competitors, including 30 funded and 2 that have exited. Its top competitors include companies like Pandorum, InSphero and Newcells Biotech.
Company Details
Pear Bio develops microfluidic chip for cancer drug research. The device combines tissue engineering, microfluidics, and biomaterials to represent how drugs are infused, distributed and exposed to the tumor over multiple passes during a chemo regimen. It also maps the spread of cancer using 3D imaging.
- Website
- pearbio.com
Key Metrics
Founded Year
2017
Location
London, United Kingdom
Stage
Series A
Total Funding
$14.2M in 3 rounds
Latest Funding Round
Investors
Ranked
9th among 91 active competitors
Employee Count
8 as on Sep 30, 2026
Similar Companies
Legal entities associated with Pear Bio
Pear Bio is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Ourotech, Inc. CIN: 0001737490 , United States, Active | - | 4 (As on Dec 31, 2024) | - | |
OUROTECH LIMITED CIN: 12288322 , United Kingdom, Active | Oct 28, 2019 | - | 29 (As on Dec 31, 2024) |
Sign up to download Pear Bio's company profile
Pear Bio's funding and investors
Pear Bio has raised a total funding of $14.2M over 3 rounds. Its first funding round was on 2017. Its latest funding round was a Series A round on Apr 14, 2023 for $*****. 6 investors participated in its latest round. Pear Bio has 11 institutional investors.
Here is the list of recent funding rounds of Pear Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 14, 2023 | 5524963 | Series A | 9028266 | 7839056 | 3858312 | 6532502 |
Jan 15, 2019 | 3808081 | Seed | 2981371 | 4443323 | 4045385 | |
2017 | 8415 | Grant (prize money) | 2247 | 4395 | 1380 |
View details of Pear Bio's funding rounds and investors
Pear Bio's founders and board of directors
Founder? Claim ProfileThe founders of Pear Bio is Duleek Ranatunga. Duleek Ranatunga is the CEO of Pear Bio.
Here are the details of Pear Bio's key team members:
- Duleek Ranatunga: Founder & CEO of Pear Bio. Contact Info: 1 email address
View details of Pear Bio's Founder profiles and Board Members
Pear Bio's employee count trend
Pear Bio has 8 employees as of Sep 26. Here is Pear Bio's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Pear Bio's Competitors and alternates
Top competitors of Pear Bio include Pandorum, InSphero and Newcells Biotech. Here is the list of Top 10 competitors of Pear Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of regenerative medicine and 3D tissues | $52.1M | 65/100 | ||
2nd | InSphero 2009, Schlieren (Switzerland), Series D | Developer of cell based assays for drug screening | $35M | 62/100 | |
3rd | Newcells Biotech 2014, Newcastle Upon Tyne (United Kingdom), Series B | Developer of induced pluripotent stem cells derived organoid models for research application | $14.4M | 59/100 | |
4th | Parallel Bio 2020, Cambridge (United States), Series A | Limited information available | $25.4M | 54/100 | |
5th | OncoPrecision 2020, Cordoba (Argentina), Seed | Developer of personalized assays for oncology precision therapy | $4.2M | 51/100 | |
6th | ![]() Nextandbio 2019, Seoul (South Korea), Series A | Provider of organoid technology to develop customized treatments for patients | $5.27M | 48/100 | |
7th | Xilis 2019, Durham (United States), Series B | Developer of drug discovery and precision therapy platform for oncology | $116M | 46/100 | |
8th | Developer of cell-based functional assays for cancer metastasis focused drug discovery and predictive diagnostics | $1.29M | 44/100 | ||
9th | Pear Bio 2017, London (United Kingdom), Series A | Developer of microfluidic chip for cancer drug research | $14.2M | 44/100 | |
10th | BioDimension 2021, Bengaluru (India), Seed | Developer of biofabricating human tissues and organoids to make research | $983K | 44/100 |
Looking for more details on Pear Bio's competitors? Click here to see the top ones
Pear Bio's Investments and acquisitions
Pear Bio has made no investments or acquisitions yet.
Reports related to Pear Bio
Here is the latest report on Pear Bio's sector:
News related to Pear Bio
•
Cytiva, Pear Bio Partner on Personalized Cancer MedicineContract Pharma•Sep 26, 2024•Cytiva, Pear Bio
•
Pear Bio Secures $14 Million Series A Funding to Advance Predictive Cancer TreatmentSilicon Valley Journals•May 17, 2023•Pear Bio, Octopus Ventures, Hoxton Ventures, Crista Galli Ventures and 2 others
•
Are you a Founder ?
FAQs about Pear Bio
Explore our recently published companies
- Solar NRJ - Czech Republic based, 2026 founded, Unfunded company
- HOP - San Francisco based, 2019 founded, Unfunded company
- Subteno - Alencon based, 2008 founded, Unfunded company
- Rebel Geek - Unfunded company
- EmailSoftwares - Unfunded company
- PRO IN - India based, 2018 founded, Unfunded company

